|Short description of Indicator
||Five-year relative survival ratio: the proportion of people alive 5 years after their diagnosis, divided by the survival expected among people of the same age, sex and time period in the general population using population life tables.
One-year relative survival ratio: the proportion of people alive 1 year after their diagnosis, divided by the survival expected among people of the same age, sex and time period in the general population using population life tables.
|Rationale for measurement
||Relative survival compares the survival experience of individuals with cancer to that of the general population of the same age and sex. It shows the extent to which a diagnosis of cancer shortens a life span. As it reflects both disease severity and prognosis, relative survival is used as an indicator for several aspects of cancer control, including monitoring progress in treatment and early detection (i.e., screening).
|Evidence/references for rationale
||This is a well-established cancer burden indicator, described and reported on by numerous provincial, national and international organizations, including:
Additional evidence supporting the utility of this measure is described in:
- Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006; 260(2):103–17.
- Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014; 2014(49):145-86
|Calculations for the indicator
||Five-year relative survival ratio (age-standardized):
- For cases diagnosed in the most recent 5-year time period, for which 5 years of follow-up data are not available for all cases, 5-year relative survival is estimated using period method. The period method observes, in the most recent time period possible, the survival of patients diagnosed in different calendar years, to estimate the survival expected for recently diagnosed cases.
- Cases are censored when they reach 100 years of age, to adjust for potential data limitations, such as the fact that many people die in other jurisdictions without notification to Ontario.
- Cases with unknown age at diagnosis, diagnosed under the age of 15 years, diagnosed on the basis of an autopsy only, and those whose date of diagnosis and date of death are the same (that is, who were only diagnosed at or following death) are excluded.
- Relative survival ratios are age-standardized by first calculating survival for 5 age groups (15 to 44, 45 to 54, 55 to 64, 65 to 74, 75 to 99). The age-specific survival estimates are then weighted using the International Cancer Survival Standard weights, which fall into 3 weighting categories based on cancer type: cancers common in younger people, cancers common in middle-aged people and all other cancers. The exception is prostate cancer, for which 5 different age groups are used (15 to 54, 55 to 64, 65 to 74, 75 to 84, 85 to 99) and the standard weights are summed for the 15 to 44 and 45 to 54 age groups.
- Adjustment for the expected mortality of people of the same age in the general population of Ontario is carried out using Ontario life tables.
- Relative survival estimates are based on 1 cancer case per SEER recode site group, per person. Multiple primary cancers captured by the Ontario Cancer Registry's new National Cancer Institute Surveillance Epidemiology and End Results (NCI SEER) program standards for counting multiple primary cancers, which were adopted by the Ontario Cancer Registry for cases diagnosed in 2010 and beyond, were excluded. If a person still has more than 1 cancer case per site after SEER multiple primary cancers are removed, then only the first primary diagnosis for the cancer site was used for survival analysis.
5-year survival analysis:
- Cases diagnosed in 2012 to 2016 (breast [ICD-O-3 code: C50.0–C50.9], colorectal [ICD-O-3 code: C18.0–C20.9, C26.0], lung [ICD-O-3 code: C34.0–C34.9], prostate [ICD-O-3 code: C61.9]).
- Cases diagnosed in 2014 to 2018 (diffuse large B-cell lymphoma, multiple myeloma, acute myeloid leukemia, acute lymphocytic leukemia).
- Survival was measured from the date of diagnosis to whichever came first: the date of death; the date of the 100th birthday; or December 31, 2016, if alive.
1-year survival analysis:
- Cases diagnosed in 2017 to 2018 (diffuse large B-cell lymphoma, multiple myeloma, acute myeloid leukemia, acute lymphocytic leukemia).
- Survival was measured from the date of diagnosis to whichever came first: the date of death; the date of the 100th birthday; or December 31, 2018, if alive.
- Brenner H, Gefeller O. Deriving more up-to-date estimates of long-term patient survival J Clin Epidemiol 1997;40:211–6.
- Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004;40:2307–16
|Standardized Rate Calculation
||Ontario Cancer Registry, 2018 (Ontario Health [Cancer Care Ontario])
- On October 29, 2014, the Ontario Cancer Registry Information System (OCRIS) was formally decommissioned and replaced with the new Ontario Cancer Registry (OCR). This change brings the registry in line with current Canadian and U.S. standards for tracking cancer incidence. The OCR now conforms to specific standards as set out by the National Cancer Institute’s Surveillance, Epidemiology and End Results (NCI SEER) program for counting multiple primary cancer sites, which most Canadian provinces and U.S. states now use. The adoption of specific NCI SEER standards with the new OCR has resulted in an increase in the incidence number of certain types of cancer reported in Ontario. To mitigate the impact of this change on survival estimates, relative survival estimates are based on 1 cancer case per SEER recode site group, per person as noted in the calculations section above.
- Cancers were defined using U.S. Surveillance, Epidemiology and End Results (SEER) Recode definitions. Cancer definitions using SEER Recode may differ, especially for cancers of the colon and rectum and lung cancer, from definitions in other published analyses of survival.
- Age-standardizing 5-year relative survival ratios and conditional 5-year relative survival ratios allows for comparison across time periods and jurisdictions by adjusting for differences in the age-distributions of the populations of interest.
- Relative survival is a useful population-based indicator of the burden of cancer and the variation in severity of different types of cancer. It does not necessarily reflect a person's chance of surviving for a given time after diagnosis.
- The Ontario Cancer Registry does not actively follow cases and so deaths may be missed. This, and the exclusion of individuals whose date of diagnosis is their date of death, may lead to overestimates of survival.
- Relative survival estimates can be biased and can over-estimate or under-estimate survival if there is a mismatch between the life table and the cancer patient cohort. In some cases, age-standardized relative survival estimates over 100% are possible, suggesting that survival in the cancer patient cohort was higher than the expected survival in a comparable group from the general population, as measured by national life tables. This can happen when:
- information on deaths is missing in the registry
- life tables do not reflect the background mortality experience of the population from which the cancer patient originated
- when cancer patients are successfully treated for their cancer and other comorbidities and, as a result, adopt a healthier lifestyle
- Ellison LF. Estimating relative survival for cancer: An analysis of bias introduced by outdated life tables. Health Rep 2014; 25:13-19.
|Data availability & limitations
- For solid tumours, 5-year relative survival ratios are shown through 2016, and for hematologic cancers survival is shown through 2018.
- Five-year survival ratio are shown for the most recent year for which the Ontario Cancer Registry had received complete date of death information at the time of analysis.